Venus Remedies Limited

NSEI:VENUSREM 株式レポート

時価総額:₹4.5b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Venus Remedies 過去の業績

過去 基準チェック /56

Venus Remediesは、平均年間34.2%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間17% 10.5%収益成長率で 成長しています。 Venus Remediesの自己資本利益率は5.8%であり、純利益率は4.7%です。

主要情報

26.5%

収益成長率

25.9%

EPS成長率

Pharmaceuticals 業界の成長17.5%
収益成長率9.5%
株主資本利益率5.9%
ネット・マージン4.6%
次回の業績アップデート14 Nov 2024

最近の業績更新

Recent updates

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17
Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14
Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13
Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14
Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Oct 31
Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Jun 03
Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Jul 15
Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

May 31
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30
I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24
Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16
Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11
Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14
We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23
Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22
Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

収支内訳

Venus Remedies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:VENUSREM 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
30 Jun 246,1492851,734165
31 Mar 246,0142851,697158
31 Dec 235,6192901,596158
30 Sep 235,3542551,527190
30 Jun 235,0762091,384203
31 Mar 235,5552661,397229
31 Dec 225,4181571,353261
30 Sep 225,4921811,352249
30 Jun 226,1193591,332267
31 Mar 226,0024071,281230
31 Dec 215,7027561,225193
30 Sep 215,6848161,214182
30 Jun 215,0877151,243149
31 Mar 215,4816181,378158
31 Dec 205,3202131,471159
30 Sep 204,939871,431158
30 Jun 204,586-401,338144
31 Mar 203,407-1001,100143
31 Dec 193,490-1611,026147
30 Sep 193,281-269995145
30 Jun 193,286-269960149
31 Mar 193,219-286928147
31 Mar 183,724-307972306
31 Mar 174,000-171409278
31 Mar 164,183174370
31 Mar 154,640524960
31 Mar 145,416643775167

質の高い収益: VENUSREMは 高品質の収益 を持っています。

利益率の向上: VENUSREMの現在の純利益率 (4.6%)は、昨年(4.1%)よりも高くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: VENUSREM過去 5 年間で収益を上げており、収益は年間34.2%増加しています。

成長の加速: VENUSREMの過去 1 年間の収益成長率 ( 36.8% ) は、5 年間の平均 ( 年間26.5%を上回っています。

収益対業界: VENUSREMの過去 1 年間の収益成長率 ( 36.8% ) はPharmaceuticals業界18.9%を上回りました。


株主資本利益率

高いROE: VENUSREMの 自己資本利益率 ( 5.8% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘